Yiyu Lu

Yiyu Lu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YLYiyu Lu
Yiyu Lu
TSTing Shen
Ting Shen
HYHua Yang
Hua Yang
WGWeiguang Gu
Weiguang Gu
Ruthenium (Ru) complexes are currently the focus of substantial interest because of their potential application as chemotherapeutic agents with broad anticancer activities. This study investigated the in vitro and in vivo anticancer activities and mechanisms of two Ru complexes—2,3,7,8,12,13,17,18-Octaethyl-21H,23H-porphine Ru(II) carbonyl (Ru1) and 5,10,15,20-Tetraphenyl-21H,23H-porphine Ru(II) carbonyl (Ru2)—against human hepatocellular carcinoma (HCC) cells. These Ru complexes effectively inhibited the cellular growth of three human hepatocellular carcinoma (HCC) cells, with IC50 values ranging from 2.7–7.3 μM. In contrast, the complexes exhibited lower toxicity towards L02 human liver normal cells with IC50 values of 20.4 and 24.8 μM, respectively. Moreover, Ru2 significantly inhibited HepG2 cell migration and invasion, and these effects were dose-dependent. The mechanistic studies demonstrated that Ru2 induced HCC cell apoptosis, as evidenced by DNA fragmentation and nuclear condensation, which was predominately triggered via caspase family member activation. Furthermore, HCC cell treatment significantly decreased the expression levels of Nrf2 and its downstream effectors, NAD(P)H: quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO1). Ru2 also exhibited potent in vivo anticancer efficacy in a tumor-bearing nude mouse model, as demonstrated by a time- and dose-dependent inhibition on tumor growth. The results demonstrate the therapeutic potential of Ru complexes against HCC via Nrf2 pathway regulation.

8 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BCBinbin Cheng
Binbin Cheng
YSYaru Shi
Yaru Shi
CSChuxiao Shao
Chuxiao Shao
SWShuanghu Wang
Shuanghu Wang
ZSZhenhong Su
Zhenhong Su
JXJian Xiao
Jian Xiao

1 June 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ZLZhihua Li
Zhihua Li
HGHaiyan Guo
Haiyan Guo
YLYiyu Lu
Yiyu Lu
JHJianxin Hu
Jianxin Hu
HLHaitao Luo
Haitao Luo
WGWeiguang Gu
Weiguang Gu
Purpose: The development of acquired resistance to the first-line epidermal growth factor-tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC) is inevitable, and most of these patients needed second-line chemotherapy. Furthermore, the optimum chemotherapeutic regimen is unclear. The aim of this meta-analysis was to evaluate the chemotherapeutic regimens “with-pemetrexed” versus “non-pemetrexed” in advanced NSCLC patients who had progressed after first-line EGFR-TKIs. Materials and methods: We searched PubMed, Embase, Cochrane Library, and the Web of science for relevant clinical trials. Outcomes analyzed were response rate (RR), disease control rate (DCR), 1-year survival rate (1-year SR), progression-free survival (PFS), and overall survival (OS). Results: One randomized controlled trial (RCT) and three retrospective studies were included in this meta-analysis, covering a total of 354 patients. The results showed that there was no significant difference between with-pemetrexed arm and non-pemetrexed arm in RR (OR 1.43, 95% CI 0.85–2.41, P=0.18), DCR (OR 1.5, 95% CI 0.94–2.39, P=0.09), and 1-year SR (OR 1.47, 95% CI 0.79–2.74, P=0.22). But the with-pemetrexed chemotherapeutic regimens significantly improved the PFS (HR 0.61, 95% CI 0.46–0.81, P=0.0005) and OS (HR 0.62, 95% CI 0.42–0.90, P=0.01). Conclusion: The second-line with-pemetrexed chemotherapeutic regimens provided significantly longer PFS and OS than non-pemetrexed chemotherapeutic regimens. These findings indicate that the with-pemetrexed chemotherapeutic regimen may be an optimal second-line chemotherapeutic regimen for patients with advanced NSCLC following EGFR-TKI failure.

7 October 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYiyu Lu
Yiyu Lu
WGWeiguang Gu
Weiguang Gu
JDJin Deng
Jin Deng
HYHua Yang
Hua Yang
WYWen Yang
Wen Yang
Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described. This study aimed to assess concurrent pemetrexed, nedaplatin and thoracic intensity-modulated radiotherapy followed by consolidation pemetrexed/nedaplatin for unresectable Stage IIIA/B lung adenocarcinoma. Patients with unresectable stage III lung adenocarcinoma received thoracic intensity-modulated radiotherapy at 60–64 Gy in 30–32 fractions, concurrently with two cycles of 500 mg/m2 pemetrexed, with nedaplatin doses escalating from 60 mg/m2 (level 1) to 70 mg/m2 (level 2) and 80 mg/m2 (level 3). Consolidation consisted of three pemetrexed/nedaplatin (500 mg/m2, 60 mg/m2) cycles every 3 weeks after concurrent therapy. The primary objective of the safety was to determine the maximum-tolerated dose (MTD). The secondary endpoints included response rate, PFS and OS. Fifteen patients were enrolled, including 3, 6 and 6 individuals in the first, second, and third dose levels, respectively. Three cases of dose-limiting toxicities (grade 3 hepatitis, pneumonitis, and grade 4 thrombocytopenia), including one and two patients at levels 2 and 3, respectively, were observed and resulted in discontinued/delayed treatment. Response rates were 86.7 % (95 % confidence interval [CI], 64.2–97.8 %) and 64.3 % (95 % CI, 38.3–85.4 %) at chemoradiation and treatment completions, respectively. Median OS was 30.0 months (95 % CI, 16.4–43.6 months); 2-year OS was 44.0 % (95 % CI, 18.7–69.2 %). Median PFS was 12.0 months (95 % CI, 6.9–17.0 months), and the 2-year PFS 27.0 % (95 % CI, 4.7–49.3 %). Full dose 500 mg/m2 of pemetrexed and nedaplatin 70 mg/m2 could be used safely with thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. Further evaluation of stage III lung adenocarcinoma management is warranted. This study was retrospectively registered at Chinese Clinical Trial Registry (ChiCTR-OPN-16008316, April 2016).

25 November 2022 in Medicine
Verified
Journal Article
Open access
YWYa-Nan Wan
Ya-Nan Wan
HCHaiming Chen
Haiming Chen
XLXin-Fu Liu
Xin-Fu Liu
WGWeiguang Gu
Weiguang Gu
YLYiyu Lu
Yiyu Lu
This study aimed to analyze the predictive value of the neutrophil-to-lymphocyte ratio (NLR) to better clarify which patients with advanced non-small cell lung cancer (NSCLC) would benefit most from apatinib after multiline treatment for drug resistance. This observational cohort study involved patients with advanced NSCLC who were treated with apatinib between May 2016 to May 2018. The participants in this study had previously been treated with at least two treatment regimens. Multivariate logistic regression and Cox proportional risk models were used to evaluate the overall survival (OS) and progression-free survival (PFS) of the pretreatment NLR. A total of 125 patients were reviewed. The median age was 64 years (range, 33–92); and 32.8% of the patients were female. Only 0.8% of the patients had an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score ≥ 2. In multivariate analysis, pretreatment NLR ≥ 5 had an independent correlation with inferior OS (median 2.07 vs 3.40 months; HR 1.493, 95% CI 1.022–2.182; P = .038) and inferior PFS (median 1.83 vs 2.76 months; HR 1.478, 95% CI 1.015–2.153; P = .042). Elevated pretreatment NLR is associated with shorter OS and PFS in patients with advanced NSCLC treated with apatinib after multiline treatment for drug resistance.

1 October 2022 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
HHHanwen Huang
Hanwen Huang
WWWeibin Wu
Weibin Wu
YLYiyu Lu
Yiyu Lu
XPXiaofen Pan
Xiaofen Pan
Original Article The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma Hanwen Huang, Weibin Wu, Yiyu Lu, Xiaofen Pan